**5. Conclusions**

In conclusion, in patients with CD who respond to adalimumab therapy, there is a shift of intestinal microbiome from dysbiosis closer to eubiosis. Further studies about the products of microbiota (metabolomic), and about micoma and viroma, should be performed to better understand the relationship between CD and microbiota.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2077-0383/8/10/1646/s1, Table S1: Relationship between bacterial populations of phyla and disease localization, Table S2: Changes in phyla according to disease localization, Table S3: Relationship between bacterial populations of phyla and disease severity, Table S4: Changes in phyla according to disease severity.

**Author Contributions:** Conceptualization, R.P., M.M., E.F., G.M.S., E.B. and M.A.; Data curation, D.G.R., G.P.C., A.A. and M.C.D.; Formal analysis, A.A.; Investigation, A.A. and M.C.D.; Methodology, D.G.R. and G.P.C.; Project administration, E.F.; Software, G.P.C.; Supervision, M.M., E.F., G.M.S. and E.B.; Validation, R.P., M.M., E.F., G.M.S. and M.A.; Visualization, E.F., E.B. and M.A.; Writing—original draft, D.G.R., G.P.C. and A.A.; Writing—review and editing, R.P.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
